Arrowhead Pharmaceuticals vs BridgeBio Pharma
ARWR and BBIO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARWR and BBIO compare
BridgeBio Pharma is the larger company, worth 2.3 times as much as Arrowhead Pharmaceuticals ($15.3B against $6.7B).
BridgeBio Pharma grew revenue faster over the last twelve months (167% versus −45.6% for Arrowhead Pharmaceuticals).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARWR | BBIO |
|---|---|---|
| Size and price | ||
| Market cap | $6.7B | $15.3B |
| Share price | $47.78 | $78.30 |
| Change, 1 year | 15.4% | 18.2% |
| Change, 5 years | −32.8% | 83.6% |
| Beta (5Y) | 1.68 | 1.11 |
| Employees | 711 | 834 |
| StockData Score | ||
| Total score | 3 | 3 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 1 (better) | 0 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 15.0× (better) | 16.1× |
| P/B | 134× | – |
| FCF yield | −4.2% | −2.4% (better) |
| Growth | ||
| Revenue growth (TTM) | −45.6% | 167% (better) |
| Revenue growth, 5Y average | 26.7% | 127% (better) |
| Profitability | ||
| Gross margin | – | 94.3% |
| Operating margin | −157% | −38.5% (better) |
| Net margin | −161% | – |
| FCF margin | −63.0% | −39.1% (better) |
| Return on equity | −281% | – |
| Financial health | ||
| Interest coverage | −7.5× | −7.1× (better) |
| Current ratio | 4.14 (better) | 2.09 |
| Altman Z-score | 0.10 | 0.16 (better) |
| Piotroski F-score | 2 | – |
| Dividends and buybacks | ||
| Buyback yield | – | 1.7% |
| Shareholder yield | 0.00% | 1.7% (better) |
| Ownership | ||
| Held by institutions | 84.6% | 99.4% |
| Held by insiders | 4.0% | 35.6% |
| Insider net buying, 12 months | −$36.9M (better) | −$84.8M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 8.5% | 16.6% |
Go deeper
- ARWR stock overview
- ARWR income statement
- ARWR valuation and score
- BBIO stock overview
- BBIO income statement
- BBIO valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.